Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
Haleon plc provided an update on its total voting rights and share capital. As at 28 February 2026, the company had 8,952,353,648 issued ordinary shares of £0.01 each, with 43,969,144 held as treasury shares. This leaves 8,908,384,504 ordinary shares carrying voting rights.
The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose interests or changes in interests under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc has made its preliminary full year results for the year ended 31 December 2025 available online and through the UK Financial Conduct Authority’s National Storage Mechanism. The statement can be accessed via the Haleon investor website and London Stock Exchange document link.
Reflecting strong free cash flow and organic operating profit growth, the Board is proposing a 2025 total dividend of 7.1p per ordinary share, a payout ratio of about 38% of 2025 adjusted earnings versus 37% in 2024. This includes a final dividend of 4.9p per share, subject to shareholder approval, with payment on 14 May 2026 to holders on the register as of 10 April 2026. The ex-dividend date is 9 April 2026 for ordinary shares and 10 April 2026 for ADSs, and DRIP elections are due by 24 April 2026. Haleon states it expects to grow its ordinary dividend at least in line with adjusted earnings.
A recorded results presentation by the CEO and CFO will be available from 7:00am GMT on 25 February 2026, followed by a Q&A call at 8:45am GMT with international dial-in access and a later archived webcast on the investor website.
Haleon plc reported routine share plan transactions by two senior executives under its Share Reward Plan. On 10 February 2026, General Counsel Adrian Morris acquired 31 ordinary shares at £3.956 as Partnership Shares and received 31 Matching Shares at no cost, for an aggregated volume of 62 shares. On the same date, President, Europe Jonathan Workman acquired 32 Partnership Shares at £3.956 and received 32 Matching Shares at no cost, an aggregated 64 shares. All transactions involved ordinary shares of £0.01 each, traded on the London Stock Exchange.
Wellington Management Group LLP and related entities report their ownership of Haleon plc common stock on an amended Schedule 13G. As of 12/31/2025, they beneficially own 443,046,686 shares, representing 4.97% of the class, with shared voting and dispositive power through investment adviser clients.
The securities are held in the ordinary course of business by Wellington-managed clients and are not held for the purpose of changing or influencing control of Haleon. No individual client is reported to hold more than five percent of the class.
Haleon plc has updated its share capital and voting rights information. As at 31 January 2026, the company has issued 8,952,353,648 ordinary shares of £0.01 each, of which 45,557,120 shares are held in treasury. This leaves 8,906,796,528 ordinary shares with voting rights.
Shareholders and others with notification obligations under the FCA's Disclosure Guidance and Transparency Rules are instructed to use the voting-rights figure as the denominator when assessing whether they must report their holdings or changes in their interest in Haleon.
Haleon plc filed a report noting an additional external role for its Chief Financial Officer. Dawn Allen, Haleon’s CFO, has been appointed Chair of the Audit & Risk Committee of ITV plc, effective 5 March 2026. She has already been serving as a Non-Executive Director of ITV and a member of its Audit & Risk Committee since 2 October 2023.
The update is described as a director declaration made in line with Listing Rule 6.4.9R(2). Haleon also reiterates that it is a global consumer health company with a portfolio of well-known brands including Advil, Centrum, Panadol, Sensodyne, Theraflu and Voltaren.
Haleon plc outlined an evolution of its operating model to support its “Win as One” strategy, aiming to drive growth, productivity and culture, with changes expected to be implemented by mid-2026. The company has created a new Chief Growth Officer role that will oversee Category, Marketing and Strategy functions, plus a new global Commercial Excellence team, and will lead the growth and innovation agenda together with R&D, Supply Chain and new Operating Units.
Haleon is also reorganising into six Operating Units, splitting the current EMEA & LatAm region into Latin America, Middle East and Africa, and Europe, and establishing India Subcontinent as its own unit separate from Asia Pacific, while North America remains unchanged. In addition, a new Chief Transformation Officer will coordinate transformation across business processes, the operating model and technology. The CGO, CTO and each Operating Unit President will join the Executive Committee and report to CEO Brian McNamara. Further detail is expected with the Preliminary Full Year Results scheduled for 25 February 2026.
Haleon plc reported routine share transactions by two senior executives under its Share Reward Plan. The company disclosed that on 5 January 2026, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers, both classified as persons discharging managerial responsibilities (PDMRs), acquired ordinary shares in Haleon.
Each PDMR acquired 34 Partnership Shares in Haleon at a price of £3.71 per share and received an award of 34 Matching Shares at £0, giving an aggregated volume of 68 ordinary shares per person. The transactions took place on the London Stock Exchange and were reported in line with UK Market Abuse Regulation requirements.
Haleon plc reported its share count and voting rights as of 31 December 2025. The company had a total of 8,952,353,648 ordinary shares of £0.01 each in issue, of which 45,745,646 were held as treasury shares without voting rights.
After excluding treasury shares, the number of ordinary shares with voting rights was 8,906,608,002. Shareholders and others with disclosure obligations are asked to use this figure as the denominator when calculating whether they need to notify their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc announced changes to its board and committees. Alan Stewart will become Senior Independent Director when Vindi Banga is appointed Chair with effect from 1 January 2026. Stewart joined the board in September 2024 as a Non-Executive Director and Chair of the Audit & Risk Committee, and he will retain that position while also remaining on the Remuneration, Nominations & Governance and Environmental & Social Sustainability Committees.
In line with the UK Corporate Governance Code 2024, Vindi Banga will step down from the Audit & Risk Committee and the Remuneration Committee on 31 December 2025 and will become Chair of the Nominations & Governance Committee from 1 January 2026. Haleon confirmed that Banga’s remuneration as Chair will be £757,103 per annum, with further details to be included in the Company’s 2025 Annual Report & Accounts.